Exelixis's SWOT analysis: cabozantinib's strength, zanzalintinib's potential drive stock outlook

Exelixis (EXEL) reported strong Q1 2025 results, exceeding EPS estimates at $0.48 and demonstrating a 24.5% revenue increase to $2.3 billion, driven primarily by cabozantinib sales. The company projects full-year 2025 net product revenue between $1.95B and $2.05B, anticipating continued growth from cabozantinib and potential expansion into neuroendocrine tumors, pending FDA approval. Investors are focused on the development of zanzalintinib, a potential $5 billion opportunity with key data readouts expected in H2 2025; however, competition and clinical trial risks remain key considerations for Exelixis's long-term success.

Analysis

Exelixis (NASDAQ:EXEL) exhibits robust financial health, underscored by a perfect Piotroski Score of 9 and strong Q1 2025 results, where diluted net income per share reached $0.48, exceeding the $0.45 forecast, on quarterly revenue of $566.8 million. The company's revenue demonstrated impressive growth, increasing 24.5% year-over-year in the last twelve months to $2.3 billion, complemented by a high 96.8% gross margin and a 30% return on equity. Cabozantinib sales, the primary revenue source, were $515.2 million in Q1, slightly surpassing estimates, and Exelixis projects full-year 2025 net product revenue between $1.95 billion and $2.05 billion, indicating approximately 10.5% year-over-year growth. Significant future growth potential is centered on zanzalintinib, a pipeline candidate with an estimated $5 billion market opportunity, which has pivotal data readouts anticipated in the second half of 2025 for indications including colorectal and renal cell carcinoma; early Phase 1/2 data for zanzalintinib has shown promise. Simultaneously, cabozantinib is pursuing FDA approval for neuroendocrine tumors (NET) with a PDUFA date set for April 3, 2025, an expansion bolstered by its recent inclusion in NCCN guidelines. Despite possessing strong liquidity, evidenced by a current ratio of 3.5 and minimal debt, and benefiting from upward earnings revisions by eight analysts, Exelixis confronts intense competition within the oncology market and the inherent risks associated with clinical trial outcomes for zanzalintinib, alongside the eventual loss of exclusivity for cabozantinib. InvestingPro data suggests the company is undervalued relative to its Fair Value estimate, with its overall financial health rated as "GREAT".

Key Decisions for Investors

• Investors should closely monitor pivotal data readouts for zanzalintinib in H2 2025 and the FDA decision on cabozantinib for neuroendocrine tumors by April 3, 2025, as these are significant near-term catalysts.
• Consider the substantial upside potential from zanzalintinib's projected multi-billion dollar market opportunity and cabozantinib's expansion into NET, balanced against the inherent risks of clinical trial failures and increasing competitive pressures in the oncology sector.
• Evaluate Exelixis's current valuation, which InvestingPro suggests may be undervalued, in conjunction with its strong financial performance and promising pipeline, while remaining aware of the long-term necessity for successful pipeline commercialization to offset cabozantinib's eventual patent expiration.